Literature DB >> 15967975

Modern antipsychotic drugs: a critical overview.

David M Gardner1, Ross J Baldessarini, Paul Waraich.   

Abstract

Conventional antipsychotic drugs, used for a half century to treat a range of major psychiatric disorders, are being replaced in clinical practice by modern "atypical" antipsychotics, including aripiprazole, clozapine, olanzapine, quetiapine, risperidone and ziprasidone among others. As a class, the newer drugs have been promoted as being broadly clinically superior, but the evidence for this is problematic. In this brief critical overview, we consider the pharmacology, therapeutic effectiveness, tolerability, adverse effects and costs of individual modern agents versus older antipsychotic drugs. Because of typically minor differences between agents in clinical effectiveness and tolerability, and because of growing concerns about potential adverse long-term health consequences of some modern agents, it is reasonable to consider both older and newer drugs for clinical use, and it is important to inform patients of relative benefits, risks and costs of specific choices.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15967975      PMCID: PMC1150265          DOI: 10.1503/cmaj.1041064

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  80 in total

1.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.

Authors:  C M Beasley; M A Dellva; R N Tamura; H Morgenstern; W M Glazer; K Ferguson; G D Tollefson
Journal:  Br J Psychiatry       Date:  1999-01       Impact factor: 9.319

Review 3.  Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine.

Authors:  P M Wehmeier; P Heiser; H Remschmidt
Journal:  J Clin Pharm Ther       Date:  2005-02       Impact factor: 2.512

4.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

5.  Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials.

Authors:  K Wahlbeck; M Cheine; A Essali; C Adams
Journal:  Am J Psychiatry       Date:  1999-07       Impact factor: 18.112

Review 6.  Dyslipidemia and atypical antipsychotic drugs.

Authors:  Daniel E Casey
Journal:  J Clin Psychiatry       Date:  2004       Impact factor: 4.384

Review 7.  State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics.

Authors:  H J Möller
Journal:  World J Biol Psychiatry       Date:  2000-10       Impact factor: 4.132

Review 8.  Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.

Authors:  Peter M Haddad; Ian M Anderson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 9.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Authors:  Christoph U Correll; Stefan Leucht; John M Kane
Journal:  Am J Psychiatry       Date:  2004-03       Impact factor: 18.112

Review 10.  Management of the negative symptoms of schizophrenia: new treatment options.

Authors:  Hans-Jürgen Möller
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more
  91 in total

1.  Narcolepsy presenting as schizophrenia: a literature review and two case reports.

Authors:  Farid Ramzi Talih
Journal:  Innov Clin Neurosci       Date:  2011-04

2.  Exploring schizophrenia drug-gene interactions through molecular network and pathway modeling.

Authors:  Daniel K Putnam; Jingchun Sun; Zhongming Zhao
Journal:  AMIA Annu Symp Proc       Date:  2011-10-22

Review 3.  Are atypical antipsychotics safer than typical antipsychotics for treating behavioral and psychological symptoms of dementia?

Authors:  A Gurevich; V Guller; Y N Berner; S Tal
Journal:  J Nutr Health Aging       Date:  2012       Impact factor: 4.075

4.  Association of quetiapine with ischemic brain stem stroke: a case report and discussion.

Authors:  Selma BozkurtZincir; Betul F Ozdilek; Serkan Zincir
Journal:  Ther Adv Psychopharmacol       Date:  2015-08

5.  Toxicological findings in suicides - frequency of antidepressant and antipsychotic substances.

Authors:  Maximilian Methling; Franziska Krumbiegel; Sven Hartwig; Maria K Parr; Michael Tsokos
Journal:  Forensic Sci Med Pathol       Date:  2018-11-05       Impact factor: 2.007

6.  Physician patterns of metabolic screening for patients taking atypical antipsychotics: a retrospective database study.

Authors:  Charles Motsinger; Michael Slack; Melanie Weaver; Morgan Reed
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

7.  'Real world' comparison of first- and second-generation antipsychotics in regard to length of inpatient hospitalization and number of re-hospitalizations.

Authors:  Claire Advokat; Benjamin D Hill; Joseph E Comaty
Journal:  Psychiatr Q       Date:  2007-12-01

8.  Risperidone and Dysphagia in a developmentally disabled woman.

Authors:  Nancy C Brahm; Gary A Fast; Robert C Brown
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

9.  Aripiprazole as the causative agent of neuroleptic malignant syndrome: a case report.

Authors:  Daniel Molina; Leslie E Tingle; Xiaohui Lu
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

10.  Could it be Quetiapine-induced Peripartum Cardiomyopathy?

Authors:  Mandeep Kaler; Rameen Shakur; Hazel I Learner; Andrew Deaner; Richard J Howard
Journal:  Obstet Med       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.